相似文献
1
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Blood Cancer J. 2015 Oct 23;5(10):e362. doi: 10.1038/bcj.2015.86.
2
Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Acta Med Okayama. 2021 Aug;75(4):461-469. doi: 10.18926/AMO/62398.
3
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Expert Opin Drug Discov. 2016 Nov;11(11):1123-1130. doi: 10.1080/17460441.2016.1233174. Epub 2016 Sep 16.
4
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5.
5
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Int J Hematol. 2015 Jun;101(6):554-62. doi: 10.1007/s12185-015-1767-3. Epub 2015 Mar 19.
6
Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Ann Hematol. 2015 Dec;94(12):2025-32. doi: 10.1007/s00277-015-2478-9. Epub 2015 Sep 28.
7
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29.
8
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Int J Hematol. 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. Epub 2019 May 24.
9
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
J Clin Oncol. 2008 Sep 20;26(27):4473-9. doi: 10.1200/JCO.2008.17.0001. Epub 2008 Jul 14.
10
Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
Acta Haematol. 2018;139(1):12-18. doi: 10.1159/000484711. Epub 2018 Jan 5.
引用本文的文献
1
Combined Impact of Prior Polatuzumab Vedotin Plus Bendamustine and Rituximab Therapy and Myeloablative Conditioning on Early Post-Transplant BK Virus-Associated Hemorrhagic Cystitis.
J Hematol. 2025 Apr;14(2):66-73. doi: 10.14740/jh2010. Epub 2025 Jan 25.
2
Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.
Ann Hematol. 2025 Jan;104(1):841-845. doi: 10.1007/s00277-024-06150-8. Epub 2024 Dec 30.
3
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
Br J Haematol. 2024 Dec;205(6):2163-2174. doi: 10.1111/bjh.19860. Epub 2024 Oct 28.
4
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.
Hemasphere. 2024 Jun 26;8(7):e86. doi: 10.1002/hem3.86. eCollection 2024 Jul.
5
Primary Adrenal Insufficiency Triggered by Cytomegalovirus Infection after Obinutuzumab Plus Bendamustine Therapy for Follicular Lymphoma.
Intern Med. 2025 Jan 15;64(2):273-279. doi: 10.2169/internalmedicine.3334-23. Epub 2024 May 30.
6
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL.
Blood Cancer J. 2024 Apr 26;14(1):73. doi: 10.1038/s41408-024-01057-z.
7
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Blood Adv. 2024 Feb 27;8(4):878-888. doi: 10.1182/bloodadvances.2023011305.
8
A case of fatal disseminated adenovirus and drug-resistant Pneumocystis pneumonia in a patient who received chemotherapy for mantle cell lymphoma.
Clin Case Rep. 2023 Apr 22;11(4):e7220. doi: 10.1002/ccr3.7220. eCollection 2023 Apr.
9
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster.
Cancers (Basel). 2022 Nov 10;14(22):5537. doi: 10.3390/cancers14225537.
10
T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
Sci Rep. 2022 Nov 4;12(1):18696. doi: 10.1038/s41598-022-23589-9.
本文引用的文献
1
Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
Ann Hematol. 2015 Mar;94(3):515-7. doi: 10.1007/s00277-014-2182-1. Epub 2014 Aug 10.
2
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
Ann Hematol. 2014 Nov;93(11):1879-87. doi: 10.1007/s00277-014-2135-8. Epub 2014 Jun 21.
3
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3.
4
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6.
5
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
6
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21.
7
Bendamustine can severely impair T-cell immunity against cytomegalovirus.
Leuk Lymphoma. 2013 Jun;54(6):1327-8. doi: 10.3109/10428194.2012.739285. Epub 2012 Nov 15.
8
Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma.
Leuk Lymphoma. 2011 May;52(5):916-8. doi: 10.3109/10428194.2010.551573. Epub 2011 Feb 10.
9
Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.
Leuk Lymphoma. 2010 Oct;51(10):1816-21. doi: 10.3109/10428194.2010.506569.
10
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x.
Zotero 插件